Keynote 199

For patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with chemotherapy

Study of Pembrolizumab in Participants With Metastatic Castration-Resistant Prostate Cancer

This is a study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. Participants will be enrolled into one of three cohorts: Cohort 1 (participants with programmed cell death ligand 1 [PD-L1]-positive, measurable disease), Cohort 2 (participants with PD-L1 negative, measurable disease), or Cohort 3 (participants with bone-metastases and non-measurable disease).

Status:

Recruiting

Phase 2 Icon

Trial Phase

The investigational immunotherapy is being studied in a group of patients to see if it is safe and effective.

Eligibility

About the Trial

All patients who enroll in the trial will receive medication while on the study.

  • 100% will receive pembrolizumab only


Trial Purpose
18

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT02787005 Read More at clinicaltrials.gov

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Stay Informed

Sign up to receive email alerts about this trial or when a location becomes available

Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Metastatic Castration-resistant Prostate Cancer

Age range

18 — no age maximum

Gender(s)

Male

Trial Purpose

This is a study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. Participants will be enrolled into one of three cohorts: Cohort 1 (participants with programmed cell death ligand 1 [PD-L1]-positive, measurable disease), Cohort 2 (participants with PD-L1 negative, measurable disease), or Cohort 3 (participants with bone-metastases and non-measurable disease).

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

Sign up to receive an email alert when a clinical trial location in your area begins accepting patients.

    Location
    Status
  • New Orleans, Louisiana, United States, 70112
    Recruiting
  • Baltimore, Maryland, United States, 21231
    Recruiting
  • Detroit, Michigan, United States, 48201
    Recruiting
  • Detroit, Michigan, United States, 48202
    Recruiting
  • Bronx, New York, United States, 10461
    Recruiting
  • New York, New York, United States, 10021
    Recruiting
  • Bismarck, North Dakota, United States, 58501
    Recruiting
  • Philadelphia, Pennsylvania, United States, 19107
    Recruiting
  • Sioux Falls, South Dakota, United States, 57104
    Recruiting
  • Germantown, Tennessee, United States, 38138
    Recruiting
  • Houston, Texas, United States, 77030
    Recruiting
  • Salt Lake City, Utah, United States, 84112
    Recruiting
  • Fairfax, Virginia, United States, 22031
    Recruiting
  • Milwaukee, Wisconsin, United States, 53226
    Recruiting
  • Baltimore, Maryland, United States, 21201
    Recruiting
  • New York, New York, United States, 10029
    Recruiting
  • Cleveland, Ohio, United States, 44106
    Recruiting
  • Portland, Oregon, United States, 97239
    Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.

Keynote number

A unique identification code used by the sponsor to identify a specific trial.
Keynote-199

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)
keynote 199 trial logo

Call 1-888-577-8839 to contact our trial information center

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.